News | Hypertension

February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in ...

Home February 27, 2020
Home
News | Cardiovascular Surgery

February 27, 2020 — The U.S. Food and Drug Administration (FDA) sent a safety communication this week to healthcare to ...

Home February 27, 2020
Home
Videos | Tufts Medical Center

Lara Reyelt, veterinary technician and preclinical surgeon at the Interventional Research Laboratories (SIRL) at Tufts ...

Home February 26, 2020
Home
An illustration of the novel coronavirus (COVID-19) from the CDC. #coronavirus #COVID19 #COVID-2019 #2019nCoV
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

The Centers for Disease Control and Prevention (CDC) said it is working to contain the spread of the novel coronavirus ...

Home February 25, 2020
Home
A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI
Feature | Heart Valve Technology | Dave Fornell, Editor

In August 2019, the U.S. Food and Drug Administration (FDA) expanded the indication for the use of transcatheter aortic ...

Home February 24, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Stents

February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the ...

Home February 24, 2020
Home
The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 
Feature | Pharmaceuticals

February 24, 2020 — The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an ...

Home February 24, 2020
Home
Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. #heartfailure
Feature | Heart Failure | Dave Fornell, Editor

There are several new tools being added to the clinical armamentarium in the fight against heart failure (HF). These ...

Home February 21, 2020
Home
Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced care, as show here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. The operator is Nevin Kapur. Photo by Dave Fornell.
Feature | Heart Failure | Dave Fornell, Editor

There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this complex disease. However, there are numerous strategies being adopted by hospitals to better manage these patients. Presented here are three ideas hospitals are using, including creation of heart failure care teams, the use of smart algorithms and IT systems to keep better track of patients and their followup, and use of consumer wearable devices to track patients between doctor visits to identify issues early.

Home February 20, 2020
Home
A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. #coronavirus #COVID2019 #COVID19 #2019nCoV #SARS‐CoV‐2
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

(Article updated May 27, 2020) February 20, 2020 — The American College of Cardiology (ACC) released a clinical bulletin ...

Home February 20, 2020
Home
News | Stroke

February 20, 2020 — Synaptive Medical, a leader in robotic surgical visualization, announced today the company has ...

Home February 20, 2020
Home
News | Cardiovascular Business

February 20, 2020 — Siemens Healthineers has introduced CentriCare — a new, patient-centric service contract portfolio ...

Home February 20, 2020
Home
Several wearable, less-obtrusive ECG monitors fhave been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 
Sponsored Content | Feature | ECG

When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “The newer ECG devices we have now are so much less cumbersome. It’s like wearing a Band-Aid versus carrying a bulky device,” said the Greenwood, Mississippi internist. “My patients prefer the more comfortable, wire-free form factor, and the quality is as good as, or better, than the Holter,” continued Boler. “Plus, my patient compliance has increased. With the Holter, the leads sometimes come off. The patient may think the device isn’t working, so they take it off and we have to restart the process.”

Home February 19, 2020
Home
Cardiac MR, also called cardiac MRI or heart MRI, can offer data above and beyond anatomical imaging.
Feature | Magnetic Resonance Imaging (MRI) | Dave Fornell, Editor

Magnetic resonance imaging (MRI) has been described for the past few decades as a futuristic imaging technology that ...

Home February 19, 2020
Home
Subscribe Now